Business Context and Reporting Period
Company: Stevanato Group S.P.A.
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions, as well as engineering equipment for the pharmaceutical and biotechnology industries. The Group operates two segments: Biopharmaceutical and Diagnostic Solutions and Engineering.
Key Financial Metrics
| Metric (EUR Million) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 273.6 | 256.6 |
| Gross Profit | 75.2 | 69.9 |
| Gross Margin | 27.5% | 27.2% |
| Operating Profit | 38.7 | 34.6 |
| Operating Margin | 14.2% | 13.5% |
| Net Profit | 28.0 | 26.5 |
| Net Profit Margin | 10.2% | 10.3% |
| EPS (Diluted) | 0.10 | 0.10 |
| Operating Cash Flow | 75.5 | 99.8 |
| Free Cash Flow | 5.5 | 29.7 |
| Cash and Equivalents | 111.7 | 130.6 (Dec 31, 2025) |
| Total Debt (Financial Liabilities) | 452.1 | 470.9 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 6.6% year-over-year (YoY), driven by a 12.7% increase in the Biopharmaceutical and Diagnostic Solutions segment, partially offset by a 31.1% decline in the Engineering segment. On a constant currency basis, revenue grew 9.8%.
- Segment Performance:
- Biopharmaceutical and Diagnostic Solutions: High-value solutions revenue grew 16.6% YoY, driven by high-performance syringes. Gross margin decreased to 28.3% from 31.3% due to higher depreciation from new assets, unfavorable currency effects, and tariff impacts.
- Engineering: Revenue declined due to lower volumes in assembly lines and glass converting machines. However, gross margin improved significantly to 15.3% from 10.7% due to cost containment and improved project mix.
- Profitability: Operating profit increased 11.9% to EUR 38.7 million. Net profit rose 5.7% to EUR 28.0 million.
- Tax Rate: The effective tax rate increased to 28.6% from 24.5% due to the discontinuation of the Italian "IRES premiale" tax reduction regime for Nuova Ompi S.r.l. in 2026.
- Cash Flow: Operating cash flow decreased to EUR 75.5 million (from EUR 99.8 million) primarily due to changes in working capital (inventory buildup) and lower net profit before tax adjustments. Free cash flow dropped to EUR 5.5 million due to high capital expenditures.
Guidance, Outlook, and Risks
- Capacity Expansion: The Group is actively ramping up new facilities in Latina, Italy, and Fishers, Indiana (U.S.). Commercial production began in Q3 2024 for Fishers, with further line installations and validations expected throughout 2026. Latina is preparing for the next phase of ready-to-use cartridge manufacturing.
- Cost Pressures: Margins are temporarily tempered by ramp-up inefficiencies (hiring, training, validation) and higher depreciation on new assets. The Group expects these inefficiencies to abate as production reaches target levels.
- Tariffs and Trade: U.S. import tariffs imposed in April 2025 have increased material costs and impacted margins. The Group is implementing pricing actions to mitigate these effects, though they only partially offset the impact.
- Internal Controls: The Company disclosed that its internal controls over financial reporting were not effective as of December 31, 2025, due to material weaknesses. Remediation efforts are ongoing, including strengthening period-end controls and IT general controls.
- Legal and Tax: The Group received additional tax audit reports from Italian authorities regarding transfer pricing. A provision of EUR 0.4 million was recognized as a precautionary measure. Management disputes some conclusions.
Investor Verification Checklist
- Ramp-up Progress: Verify the timeline and cost absorption for the new Fishers (U.S.) and Latina (Italy) facilities to assess when margin headwinds will normalize.
- Engineering Segment Turnaround: Monitor the Engineering segment's order intake and project mix to confirm the sustainability of the margin improvement (15.3%) amidst lower revenue.
- Tariff Impact: Assess the extent to which pricing actions have successfully passed tariff costs to customers and the potential for further margin compression.
- Internal Control Remediation: Review the status of remediation for the material weaknesses in internal controls over financial reporting to ensure future reporting reliability.
- Working Capital Management: Analyze the inventory buildup (increased by EUR 26.1 million QoQ) to ensure it aligns with future demand forecasts and does not signal destocking risks.